Sunshine from Spain: Minoryx Targets Rare Genetic Diseases

Here in Berlin, we’re getting desperate for warmth and sunshine, so we moseyed on down to Barcelona to meet Minoryx Therapeutics. The company is developing a treatment for a peroxisomal disorder that leads to lifelong disability, and it’s about to enter Phase II/III.


logo

City: Barcelona, Spain

Founded: 2011

Employees: 11-50

Financial data: €24.4M total raised

Mark Martinelli Minoryx Therapeutics

Mark Martinell, CEO

Mission: Minoryx Therapeutics is focused on a group of rare genetic diseases like X-Linked Adrenoleukodystrophy (X-ALD) and other metabolic disorders that have no available treatment. The company is developing small molecules to address these diseases and sees them all the way through the clinic.

Comment: Minoryx is preparing to launch a Phase II/III trial for their X-linked adrenoleukodystrophy drug, MIN-102, early this year. To support the effort, it just recruited 5 new members to its Scientific Advisory Board from renowned institutions across Europe and the US.

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and its' freely accessible content.